A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy.
Phase of Trial: Phase III
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Sodium oxybate (Primary)
- Indications Catalepsy; Narcolepsy
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
- 15 Mar 2017 According to a Jazz Pharmaceuticals Inc media release, first patient has been enrolled in the study.
- 15 Mar 2017 Status changed from not yet recruiting to recruiting, as reported in a Jazz Pharmaceuticals Inc media release.
- 14 Nov 2016 New trial record